2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+)
C22H17N3O2Pt — CID 140695794
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+)
2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+) (PubChem CID 140695794) has the molecular formula C22H17N3O2Pt and a molecular weight of 550.48 g/mol. Its IUPAC name is 2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+).
Molecular Properties
| Compound Name | 2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+) |
|---|---|
| PubChem CID | 140695794 |
| Molecular Formula | C22H17N3O2Pt |
| Molecular Weight | 550.48 g/mol |
| Exact Mass | 550.10 |
| IUPAC Name | 2-[3-[3-(1,4-dimethylimidazol-2-yl)benzene-2-id-1-yl]oxybenzene-2-id-1-yl]oxypyridine;platinum(2+) |
| SMILES | Cc1cn(C)c(-c2[c-]c(Oc3[c-]c(Oc4ccccn4)ccc3)ccc2)n1.[Pt+2] |
| InChI | InChI=1S/C22H17N3O2.Pt/c1-16-15-25(2)22(24-16)17-7-5-8-18(13-17)26-19-9-6-10-20(14-19)27-21-11-3-4-12-23-21;/h3-12,15H,1-2H3;/q-2;+2 |
| InChIKey | NRKCKVDXNQBXCA-UHFFFAOYSA-N |
| XLogP | 4.97 |
| TPSA | 49.17 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 550.48 |
| LogP ≤ 5 | 4.97 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Carbo_cation/anion', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 140695794 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.